Lumos Pharma, Inc. (LUMO) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LUMO Hot Sheet
Join SI Premium – FREE
Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q3 EPS of ($1.04), $0.11 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $7 thousand versus the consensus estimate of $225.4 thousand.
For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
